Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells

Patients with advanced neuroblastoma (NB) receive multimodal clinical therapy, including the potent anthracycline chemotherapy drug doxorubicin (Dox). The acquisition of Dox resistance, however, is a major barrier to a sustained response and leads to a poor prognosis in advanced disease states, rein...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappabianca, Lucia, Sebastiano, Michela, Ruggieri, Marianna, Sbaffone, Maddalena, Zelli, Veronica, Farina, Antonietta Rosella, Mackay, Andrew Reay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503591/
https://www.ncbi.nlm.nih.gov/pubmed/36142807
http://dx.doi.org/10.3390/ijms231810895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503591/
https://www.ncbi.nlm.nih.gov/pubmed/36142807
http://dx.doi.org/10.3390/ijms231810895

Ejemplares similares